Table 2. Efficacy and tolerability results of overall and subgroup analyses.

	Early and advanced PD		Early PD		Advanced PD+LDa
Items	No. of trials	WMD/RR(95%CI)	No. of trials	WMD/RR(95%CI)	No. of trials	WMD/RR(95%CI)
UPDRS ADL score	4	–1.69 (–2.18, –1.19)	1	–1.31 (–2.16, –0.46)	2	–2.37 (–3.19, –1.55)
UPDRS motor score	4	–3.86 (–4.86, –2.86)	1	–3.96 (–5.74, –2.18)	2	–4.37 (–5.98, –2.75)
ADL+motor subtotal score	3	–4.52 (–5.86, –3.17)	3	–4.52 (–5.86, –3.17)	N/A	N/A
Overall withdrawals	6	0.88 (0.64, 1.21)	3	1.12 (0.84, 1.47)	2	0.69 (0.29, 1.61)
Withdrawals due to adverse events	6	1.82 (1.29, 2.59)	3	2.72 (1.57, 4.70)	2	1.40 (0.82, 2.37)

Abbreviations: UPDRS = unified Parkinson’s disease rating scale; PD = Parkinson’s disease; WMD = weighted mean difference; RR = relative risk; CI = confidence interval; LD = levodopa; ADL = activities of daily living; N/A = not available.

^a+LD indicates that patients also took levodopa during the trials.